Works matching AU Wu, Yi‐Long

Results: 132
    1
    2
    3
    4

    Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma.

    Published in:
    Clinical & Translational Immunology, 2024, v. 13, n. 6, p. 1, doi. 10.1002/cti2.1515
    By:
    • Zhong, Yu‐Min;
    • Chen, Ji;
    • Jiang, Jie;
    • Zhou, Wen‐Bin;
    • Gao, Ling‐Ling;
    • Zhang, Shui‐Lian;
    • Yan, Wen‐Qing;
    • Chen, Yu;
    • Zhang, Dong‐Kun;
    • Lu, Dan‐Xia;
    • Lv, Zhi‐Yi;
    • Xie, Zhi;
    • Huang, Ying;
    • Guo, Wei‐Bang;
    • Wang, Bin‐Chao;
    • Yang, Jin‐Ji;
    • Yang, Xue‐Ning;
    • Wu, Yi‐Long;
    • Zhang, Xu‐Chao
    Publication type:
    Article
    5
    6

    Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    Published in:
    2018
    By:
    • Wu, Yi-Long;
    • Sequist, Lecia V;
    • Tan, Eng-Huat;
    • Geater, Sarayut L;
    • Orlov, Sergey;
    • Zhang, Li;
    • Lee, Ki Hyeong;
    • Tsai, Chun-Ming;
    • Kato, Terufumi;
    • Barrios, Carlos H;
    • Schuler, Martin;
    • Hirsh, Vera;
    • Yamamoto, Nobuyuki;
    • O'Byrne, Kenneth;
    • Boyer, Michael;
    • Mok, Tony;
    • Peil, Barbara;
    • Märten, Angela;
    • Chih-Hsin Yang, James;
    • Paz-Ares, Luis
    Publication type:
    journal article
    7
    8
    9
    10
    11
    12
    13
    14

    Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

    Published in:
    Drugs, 2021, v. 81, n. 2, p. 257, doi. 10.1007/s40265-020-01441-6
    By:
    • Mok, Tony S.;
    • Cheng, Ying;
    • Zhou, Xiangdong;
    • Lee, Ki Hyeong;
    • Nakagawa, Kazuhiko;
    • Niho, Seiji;
    • Chawla, Alka;
    • Rosell, Rafael;
    • Corral, Jesus;
    • Migliorino, Maria Rita;
    • Pluzanski, Adam;
    • Noonan, Kay;
    • Tang, Yiyun;
    • Pastel, Malaika;
    • Wilner, Keith D.;
    • Wu, Yi-Long
    Publication type:
    Article
    15
    16
    17

    A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).

    Published in:
    Journal of Hematology & Oncology, 2025, v. 18, n. 1, p. 1, doi. 10.1186/s13045-024-01656-0
    By:
    • Chen, Hua-Jun;
    • Tu, Hai-Yan;
    • Hu, Yanping;
    • Fan, Yun;
    • Wu, Guowu;
    • Cang, Shundong;
    • Yang, Yi;
    • Yang, Nong;
    • Ma, Rui;
    • Jin, Gaowa;
    • Xu, Ximing;
    • Liu, Anwen;
    • Tang, Shubin;
    • Cheng, Ying;
    • Yu, Yan;
    • Xu, Chong-Rui;
    • Zhou, Qing;
    • Wu, Yi-Long
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24

    Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 6, p. 1393, doi. 10.1007/s00262-021-03091-3
    By:
    • Yang, Jin-Ji;
    • Huang, Cheng;
    • Fan, Yun;
    • Pan, Hongming;
    • Feng, Jifeng;
    • Jiang, Liyan;
    • Li, Xing-Ya;
    • Liu, Xiao-Qing;
    • Xiong, Jian-Ping;
    • Zhao, Yan-Qiu;
    • Cheng, Ying;
    • Ma, Rui;
    • Wang, Jie;
    • Wang, Yina;
    • Liu, Yan-Hui;
    • Lin, Dong-Mei;
    • Wang, Tao;
    • Shi, Wei;
    • Zou, Jianjun;
    • Wu, Yi-Long
    Publication type:
    Article
    25

    Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.

    Published in:
    Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 471, doi. 10.1007/s00262-017-2098-4
    By:
    • Zhang, Xu-chao;
    • Cao, Xu;
    • Sun, Chun;
    • Xie, Zhi;
    • Guo, Jian-jun;
    • Yang, Jin-ji;
    • Yang, Xue-ning;
    • Dai, Hang-jun;
    • Li, Su-chun;
    • Xu, Xin-ran;
    • Zuo, Yun-xia;
    • Chen, Meng;
    • Koeppen, Hartmut;
    • He, Jing;
    • Kiermaier, Astrid;
    • Shames, David;
    • Cheng, Gang;
    • Wu, Yi-long
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).

    Published in:
    Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221138380
    By:
    • Lu, Shun;
    • Cheng, Ying;
    • Zhou, Jianying;
    • Wang, Mengzhao;
    • Zhao, Jun;
    • Wang, Baocheng;
    • Chen, Gongyan;
    • Feng, Jifeng;
    • Ma, Zhiyong;
    • Wu, Lin;
    • Wang, Changli;
    • Ma, Kewei;
    • Zhang, Shucai;
    • Liang, Jun;
    • Song, Yong;
    • Wang, Jie;
    • Wu, Yi-Long;
    • Li, Ang;
    • Huang, Yizhi;
    • Chang, Jianhua
    Publication type:
    Article
    50